OBJECTIVE: To 1) compare monthly serum levels of matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of MMP-type 1 (TIMP-1) in patients with relapsing-remitting MS (RRMS) versus healthy controls and 2) determine the relationship among monthly serum levels of MMP-9 and TIMP-1 and MRI activity. BACKGROUND: Activated T-cells and macrophages secrete MMPs that may facilitate their migration across vascular subendothelial basement membranes into the CNS. The serum concentration of MMP-9 is reported to be higher in patients with RRMS than healthy controls. METHODS: Monthly evaluations including gadolinium-enhanced (Gd+) brain MRI and measures of serum MMP-9 and TIMP-1 were performed for up to 15 months in 24 patients with RRMS and for up to 4 months in 10 controls. RESULTS: Serum MMP-9 but not TIMP-1 levels are elevated in RRMS patients compared to healthy controls (p = 0.025, p = 0.61). In a univariate analysis, high MMP-9 and low TIMP-1 levels precede appearance of new Gd+ lesions (respectively; odds ratio = 3.3, p = 0.008; odds ratio = 2.2, p = 0.086). In a multivariate analysis, in comparison to months when MMP-9 is low and TIMP-1 high, MRI scans obtained the month following high MMP-9 and low TIMP-1 serum concentrations are more likely to report new Gd+ lesions (p = 0.0006, odds ratio = 21.5). CONCLUSION: An increase in the activity of matrix metalloproteinase-9 (MMP-9) relative to tissue inhibitor of MMP-type 1 (TIMP-1) may be related to formation of new MS lesions, suggesting that serum levels of MMP-9 and TIMP-1 may be surrogate markers of disease activity in relapsing-remitting MS.
OBJECTIVE: To 1) compare monthly serum levels of matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of MMP-type 1 (TIMP-1) in patients with relapsing-remitting MS (RRMS) versus healthy controls and 2) determine the relationship among monthly serum levels of MMP-9 and TIMP-1 and MRI activity. BACKGROUND: Activated T-cells and macrophages secrete MMPs that may facilitate their migration across vascular subendothelial basement membranes into the CNS. The serum concentration of MMP-9 is reported to be higher in patients with RRMS than healthy controls. METHODS: Monthly evaluations including gadolinium-enhanced (Gd+) brain MRI and measures of serum MMP-9 and TIMP-1 were performed for up to 15 months in 24 patients with RRMS and for up to 4 months in 10 controls. RESULTS: Serum MMP-9 but not TIMP-1 levels are elevated in RRMS patients compared to healthy controls (p = 0.025, p = 0.61). In a univariate analysis, high MMP-9 and low TIMP-1 levels precede appearance of new Gd+ lesions (respectively; odds ratio = 3.3, p = 0.008; odds ratio = 2.2, p = 0.086). In a multivariate analysis, in comparison to months when MMP-9 is low and TIMP-1 high, MRI scans obtained the month following high MMP-9 and low TIMP-1 serum concentrations are more likely to report new Gd+ lesions (p = 0.0006, odds ratio = 21.5). CONCLUSION: An increase in the activity of matrix metalloproteinase-9 (MMP-9) relative to tissue inhibitor of MMP-type 1 (TIMP-1) may be related to formation of new MS lesions, suggesting that serum levels of MMP-9 and TIMP-1 may be surrogate markers of disease activity in relapsing-remitting MS.
Authors: Elizabeth Milward; Kee Jun Kim; Arek Szklarczyk; Thien Nguyen; Giorgia Melli; Mamatha Nayak; Deepa Deshpande; Chantel Fitzsimmons; Ahmet Hoke; Douglas Kerr; John W Griffin; Peter A Calabresi; Katherine Conant Journal: J Neuroimmunol Date: 2007-12-11 Impact factor: 3.478
Authors: Jiehao Zhou; Norman W Marten; Cornelia C Bergmann; Wendy B Macklin; David R Hinton; Stephen A Stohlman Journal: J Virol Date: 2005-04 Impact factor: 5.103
Authors: L Shinto; G Marracci; S Baldauf-Wagner; A Strehlow; V Yadav; L Stuber; D Bourdette Journal: Prostaglandins Leukot Essent Fatty Acids Date: 2009-01-25 Impact factor: 4.006
Authors: Stefan M Gold; Manda V Sasidhar; Laurie B Morales; Sienmi Du; Nancy L Sicotte; Seema K Tiwari-Woodruff; Rhonda R Voskuhl Journal: Lab Invest Date: 2009-08-10 Impact factor: 5.662
Authors: Isobel A Scarisbrick; Rachel Linbo; Alexander G Vandell; Mark Keegan; Sachiko I Blaber; Michael Blaber; Diane Sneve; Claudia F Lucchinetti; Moses Rodriguez; Eleftherios P Diamandis Journal: Biol Chem Date: 2008-06 Impact factor: 3.915